Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound--initial results.
The purpose of this study was to monitor liver metastases after radiotherapy using contrast-enhanced ultrasound (CEUS). In 15 patients, follow-up examinations after stereotactic, single-dose radiotherapy were performed using CEUS (low mechanical index (MI), 2.4-ml SonoVue) and computed tomography (CT). Besides tumor size, the enhancement of the liver and the metastases was assessed at the arterial, portal venous, and delayed phases. The sizes of the tumor and of a perifocal liver reaction after radiotherapy measured with CEUS significantly correlated with those measured at CT (r=0.93, p<0.001). CEUS found a significant reduction of the arterial vascularization in treated tumors (p<0.05). In the arterial phase, the perifocal liver tissue was hypervascularized compared to the treated tumor (p<0.001); in the late phase, it was less enhanced than the liver (p<0.001) and more than the tumor (p<0.01). The perifocal liver reaction was also seen in CT, but with a variable enhancement at the arterial (50% hyperdense compared to normal liver tissue), venous, or delayed phase (each with 70% hyperdense reactions). CEUS allows for the assessment of tumor and liver perfusion, in addition to morphological tumor examination, which was comparable with CT. Thus, changes of tumor perfusion, which may indicate tumor response, as well as the perifocal liver reaction after radiotherapy, which must be differentiated from perifocal tumor growth, can be sensitively visualized using CEUS.
Krix
M
M
German Cancer Research Center--Radiology, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. m.krix@dkfz.de
Plathow
C
C
Essig
M
M
Herfarth
K
K
Debus
J
J
Kauczor
H-U
HU
Delorme
S
S
D003287:Contrast Media; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D008279:Magnetic Resonance Imaging; D008297:Male; D011446:Prospective Studies; D014463:Ultrasonography
D003287:Contrast Media
Circulation. 1998 Feb 10;97(5):473-83
9490243
Cancer. 2004 Mar 15;100(6):1246-56
15022293
Ann Surg. 2003 Feb;237(2):171-9
12560774
Acta Radiol. 2001 Sep;42(5):526-31
11552892
J Comput Assist Tomogr. 1999 Sep-Oct;23 (5):655-63
10524841
Eur Radiol. 1999;9(4):675-84
10354884
Eur Radiol. 2004 Jun;14 (6):1092-9
15007620
Eur Radiol. 2003 Mar;13(3):475-83
12594549
Eur Radiol. 2004 Jun;14 (6):1082-91
15108017
Cell Tissue Res. 2003 Apr;312(1):49-54
12712317
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):444-51
12957256
Invest Radiol. 2000 Jan;35(1):58-71
10639037
Strahlenther Onkol. 2000 Dec;176(12):567-72
11140151
Eur Radiol. 2002 Jan;12 (1):151-65
11868093
Strahlenther Onkol. 2001 Dec;177(12):645-55
11789403
J Clin Oncol. 2001 Jan 1;19(1):164-70
11134209
AJR Am J Roentgenol. 1995 Jul;165(1):79-84
7785638
J Magn Reson Imaging. 2000 Dec;12(6):1027-33
11105046
Cancer. 1981 Jan 1;47(1):207-14
7459811
Eur Radiol. 2004 Jun;14 (6):1100-8
14676975
Lancet. 2000 Mar 4;355(9206):807-8
10711932
Invest Radiol. 2004 Apr;39(4):216-22
15021325
Arch Pathol Lab Med. 1980 Nov;104(11):584-8
6893535
J Clin Ultrasound. 2002 Oct;30(8):465-71
12242734
Ultrasound Med Biol. 2004 Jun;30(6):851-4
15219964
Z Gastroenterol. 2004 Jan;42(1):31-8
14997401
Rofo. 2003 Oct;175(10 ):1403-12
14556110
N Engl J Med. 1991 Jan 3;324(1):1-8
1701519